Page 8 - Celcuity Inc News Today

First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan trancheMINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage

MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced

Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancerEntered into agreements for the private placement sale of $100 million of equity and to increase available

MINNEAPOLIS, MN / ACCESSWIRE / August 3, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced

MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced

Sera Prognostics (NASDAQ:SERA – Get Rating) and Celcuity (NASDAQ:CELC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Analyst Ratings This is a summary of recent recommendations and […]

Sera Prognostics (NASDAQ:SERA – Get Rating) and Celcuity (NASDAQ:CELC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Insider & Institutional Ownership 63.2% of Sera Prognostics shares are […]

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients

Investment Analysts’ updated eps estimates for Friday, May 20th: Avidbank (OTCMKTS:AVBH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $24.00 target price on the stock. According to Zacks, “Avidbank Holdings, Inc. is a locally owned and managed, California State chartered commercial bank. […]

Celcuity (NASDAQ:CELC – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. The brokerage presently has a $6.25 price target on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 9.65% […]